Company profile for Antibe Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Antibe Therapeutics (“Antibe”) is a public biotech company with a drug platform of game-changing therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety, and its combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe’s commercial division in regenerative medicine is on a growth trajectory in the dental biologics m...
Antibe Therapeutics (“Antibe”) is a public biotech company with a drug platform of game-changing therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety, and its combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe’s commercial division in regenerative medicine is on a growth trajectory in the dental biologics market.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
15 Prince Arthur Avenue Toronto, Ontario M5R 1B2 Canada
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Antibe Announces Completion of Sale
Antibe Announces Completion of Sale

18 Mar 2025

// GLOBENEWSWIRE

https://www.globenewswire.com//news-release/2025/03/18/3044874/0/en/Antibe-Announces-Completion-of-Sale.html

GLOBENEWSWIRE
18 Mar 2025

https://www.expresspharma.in/sun-pharma-subsidiary-taro-acquires-antibe-therapeutics/

EXPRESSPHARMA
16 Jan 2025
Antibe Announces Appointment of Receiver
Antibe Announces Appointment of Receiver

24 Apr 2024

// BUSINESSWIRE

https://www.businesswire.com/news/home/20240424042966/en

BUSINESSWIRE
24 Apr 2024

https://www.businesswire.com/news/home/20240419229842/en

BUSINESSWIRE
19 Apr 2024
Antibe Announces TSX Delisting Review
Antibe Announces TSX Delisting Review

16 Apr 2024

// BUSINESSWIRE

https://www.businesswire.com/news/home/20240416152611/en

BUSINESSWIRE
16 Apr 2024

https://www.businesswire.com/news/home/20240409669936/en

BUSINESSWIRE
10 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty